A notable insider purchase on January 24, was reported by Caroline Litchfield, EVP & CFO at Merck & Co (NYSE:MRK), based on the most recent SEC filing.
What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday unveiled that Litchfield made a notable purchase of 19,208 shares of Merck & Co, valuing at $2,294,011.
Tracking the Thursday's morning session, Merck & Co shares are trading at $119.09, showing a up of 0.18%.
About Merck & Co
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Financial Insights: Merck & Co
Revenue Growth: Over the 3 months period, Merck & Co showcased positive performance, achieving a revenue growth rate of 6.71% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, ...